Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Abstract CT184: Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo)
Conference Cancer Research · April 17, 2026 AbstractPatients (pts) with metastatic (met) MSS CRC are treated with sequential lines of chemotherapy (chemo), but most experience progression and prolonged toxicities during their disease course. BOT is ... Full text CiteAbstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress)
Conference Cancer Research · April 17, 2026 AbstractBackground:Fibroblast activation protein (FAP) is a transmembrane glycoprotein highly expressed on cancer-associated fi ... Full text CiteImmune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience.
Journal article ESMO Open · January 2026 BACKGROUND: Prospective, single-institution studies in deficient DNA mismatch repair (dMMR) locally advanced rectal cancer (LARC) have shown high rates of complete clinical response (cCR) to neoadjuvant immune checkpoint inhibitor (ICI) monotherapy. PATIEN ... Full text Link to item CiteRecent Grants
An Interventional Phase 3 Double Blind Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Bevacizumab in Combination with Chemotherapy in Treatment-Naive Participants with Metastatic Colorectal
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2031Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colore
Clinical TrialPrincipal Investigator · Awarded by Endevica Bio · 2025 - 2030Effectiveness of T-DXd across HER2-positive solid tumors in patients who have received prior systemic treatment and have no satisfactory alternative treatment options: A hybrid observational study
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca UK Limited · 2025 - 2030View All Grants
Education
Maulana Azad Medical College (India) ·
2011
M.B.B.S.